Literature DB >> 16716629

Rskalpha-actin/hIGF-1 transgenic mice with increased IGF-I in skeletal muscle and blood: impact on regeneration, denervation and muscular dystrophy.

T Shavlakadze1, J M Boswell, D W Burt, E A Asante, F M Tomas, M J Davies, J D White, M D Grounds, C Goddard.   

Abstract

Human IGF-I was over-expressed in skeletal muscles of C57/BL6xCBA mice under the control of the rat skeletal alpha-actin gene promoter. RT-PCR verified expression of the transgene in skeletal muscle but not in the liver of 1- and 21-day old heterozygote transgenic mice. The concentration of endogenous mouse IGF-I, measured by an immunoassay which does not detect human IGF-I, was not significantly different between transgenic mice and wild-type littermates (9.5 +/- 0.8 and 13.3 +/- 1.9 ng/g in muscle; 158.3 +/- 18.6 and 132.9 +/- 33.1 ng/ml in plasma, respectively). In contrast, quantitation with antibodies to human IGF-I showed an increase in IGF-I of about 100 ng/ml in plasma and 150 ng/g in muscle of transgenic mice at 6 months of age. Transgenic males, compared to their age matched wild-type littermates, had a significantly higher body weight (38.6 +/- 0.53 g vs. 35.8 +/- 0.64 g at 6 months of age; P < 0.001), dry fat-free carcass mass (5.51 +/- 0.085 vs. 5.08 +/- 0.092 g; P < 0.001) and myofibrillar protein mass (1.62 +/- 0.045 vs. 1.49 +/- 0.048 g; P < 0.05), although the fractional content of fat in the carcass was lower (167 +/- 7.0 vs. 197 +/- 7.7 g/kg wet weight) in transgenic animals. There was no evidence of muscle hypertrophy and no change in the proportion of slow type I myofibres in the limb muscles of Rskalpha-actin/hIGF-I transgenic mice at 3 or 6 months of age. Phenotypic changes in Rskalpha-actin/hIGF-I mice are likely to be due to systemic as well as autocrine/paracrine effects of overproduction of IGF-I due to expression of the human IGF-I transgene. The effect of muscle specific over-expression of Rskalpha-actin/hIGF-I transgene was tested on: (i) muscle regeneration in auto-transplanted whole muscle grafts; (ii) myofibre atrophy following sciatic nerve transection; and (iii) sarolemmal damage and myofibre necrosis in dystrophic mdx muscle. No beneficial effect of muscle specific over-expression of Rskalpha-actin/hIGF-I transgene was seen in these three experimental models.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16716629     DOI: 10.1016/j.ghir.2005.11.003

Source DB:  PubMed          Journal:  Growth Horm IGF Res        ISSN: 1096-6374            Impact factor:   2.372


  8 in total

1.  Transcriptional regulation of the IGF signaling pathway by amino acids and insulin-like growth factors during myogenesis in Atlantic salmon.

Authors:  Neil I Bower; Ian A Johnston
Journal:  PLoS One       Date:  2010-06-14       Impact factor: 3.240

Review 2.  Regulation of muscle mass by growth hormone and IGF-I.

Authors:  C P Velloso
Journal:  Br J Pharmacol       Date:  2008-06       Impact factor: 8.739

3.  The hormonal action of IGF1 in postnatal mouse growth.

Authors:  Elias Stratikopoulos; Matthias Szabolcs; Ioannis Dragatsis; Apostolos Klinakis; Argiris Efstratiadis
Journal:  Proc Natl Acad Sci U S A       Date:  2008-11-25       Impact factor: 11.205

4.  The physiological effects of IGF-1 (class 1:Ea transgene) over-expression on exercise-induced damage and adaptation in dystrophic muscles of mdx mice.

Authors:  James A Ridgley; Gavin J Pinniger; Peter W Hamer; Miranda D Grounds
Journal:  Pflugers Arch       Date:  2008-08-26       Impact factor: 3.657

5.  New Modulators for IGF-I Activity within IGF-I Processing Products.

Authors:  Becky K Brisson; Elisabeth R Barton
Journal:  Front Endocrinol (Lausanne)       Date:  2013-03-27       Impact factor: 5.555

6.  Incorporation of a skeletal muscle-specific enhancer in the regulatory region of Igf1 upregulates IGF1 expression and induces skeletal muscle hypertrophy.

Authors:  Yunlong Zou; Yanjun Dong; Qingyong Meng; Yaofeng Zhao; Ning Li
Journal:  Sci Rep       Date:  2018-02-09       Impact factor: 4.379

7.  Functional muscle hypertrophy by increased insulin-like growth factor 1 does not require dysferlin.

Authors:  Elisabeth R Barton; Jennifer Pham; Becky K Brisson; SooHyun Park; Lucas R Smith; Min Liu; Zuozhen Tian; David W Hammers; Georgios Vassilakos; H Lee Sweeney
Journal:  Muscle Nerve       Date:  2019-07-30       Impact factor: 3.217

8.  E-peptides control bioavailability of IGF-1.

Authors:  Marianne Smedegaard Hede; Ekaterina Salimova; Agnieszka Piszczek; Emarald Perlas; Nadine Winn; Tommaso Nastasi; Nadia Rosenthal
Journal:  PLoS One       Date:  2012-12-10       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.